An observational study in Acute Heart Failure (AHF), Sarcopenia and Heart Failure, sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal. Recruiting at 1 site in Spain. Open to participants aged 80 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Sarcopenia with a site in Spain — 33 open to participants now, 40 under way, none of them phase 3. Sarcopenia · Spain.
Among the 99 studies in Sarcopenia with a site in Spain, this one is the 15th largest by planned enrollment of the 22 observational ones that give a count, is one of 16 that started in 2026, is one of 22 observational ones, reaches primary completion later than 32 of the 39 other live ones, and was the 88th registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →33 of the 99 studies in Sarcopenia with a site in Spain are open now. Recruiting first, the newest first:
University of Valencia · Sites in Spain
Ages 18–99
Universidad de Granada · Sites in Spain
Ages 65+
University of Salamanca · Sites in Spain
Ages 18+
Sara Casanova Prieto · Sites in Spain
Ages 18+
University of Salamanca · Sites in Spain
Ages 40+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 80 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 16 started in 2026.
This study's planned enrollment of 110 is close to the median of 120 across 455 observational studies indexed under Sarcopenia.
Median enrollment 72 across the 77 interventional studies, 156 across the 22 observational. Of the 48 that completed or were terminated, 2 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 99 have an industry lead sponsor. The 10 most frequent:
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal is the lead sponsor of 84 studies on the registry; 23 are open to participants now.
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal has 3 studies filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
15 of the studies in Sarcopenia with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07387770University of SalamancaMuscle Deterioration in Hospitalized Cancer Patient | 2026-11-30 |
| NCT07275996Universidad de BurgosNeuromuscular and Multi-Omics Synergy of Combined Creatine × HMB Supplementation Plus Exercise to Improve Muscle Function in Sarcopenic Frailty | 2026-12-30 |
| NCT06634316Maimónides Biomedical Research Institute of CórdobaSarcopenia in Patients With Heart Failure | 2026-12-31 |
| NCT07447375University of SalamancaExercise During Hemodialysis: Impact on Sarcopenia and Sleep Quality | 2026-12-31 |
| NCT06015971Maimónides Biomedical Research Institute of CórdobaOmega-3 Fatty Acids and Nutritional Support in Gastrointestinal Cancer | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 99 studies in Sarcopenia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Acute heart failure (AHF) is the leading cause of hospitalization in people over 65, with the group with preserved ejection fraction (HFpEF) being the most closely related to aging. Among its comorbidities, sarcopenia stands out, and its assessment requires measurement of muscle mass. Muscle ultrasound is an accessible and economical alternative, although its prognostic value is still uncertain. The presence of common pathophysiological mechanisms between HF-PEF and sarcopenia leads to the study of biomarkers to improve their characterization.
Multimodal characterization of sarcopenia, integrating muscle mass and strength with skeletal and cardiac muscle biomarkers, will improve prognostic stratification at discharge in elderly patients with HFpEF hospitalized for ACS. We seek to evaluate the prognostic value of muscle mass estimated by ultrasound, in combination with strength measurements and circulating biomarkers related to sarcopenia, as this could improve the prediction of clinical events after hospitalization for AHF in elderly patients with HFpEF. In addition, ultrasound estimation of muscle mass will be analyzed against BIA, the relationship between skeletal and cardiac muscle will be characterized, and the usefulness of the multimodal approach to sarcopenia will be evaluated.
This study is observational, prospective, and single-center. It will include 110 patients hospitalized for AHF aged ≥80 years. Events will be monitored for 6 months after discharge. Variables include clinical data, ultrasound data (lung, VExUS, and muscle mass), congestion markers (BNP, CA125), biomarkers (GDF-15, sST2, BDNF, and myostatin/follistatin), bioimpedance, and dynamometry. Data will be analyzed using regression models and survival analysis to identify prognostic factors.
This study has the potential to improve the clinical management of patients with acute heart failure by providing key information on its interaction with sarcopenia. The results could help identify more effective strategies to reduce rehospitalization and mortality in these patients, improving their prognosis and quality of life.
Patients over 80 years of age of both sexes hospitalized for AHF in the Internal Medicine or the Geriatrics wards of a tertiary care hospital, with signs of fluid overload and intravenous (IV) diuretic treatment. The clinical diagnosis of HF will be made based on the presence of typical signs and symptoms, evidence of underlying structural heart disease by transthoracic echocardiography, and elevated natriuretic peptides. Only patients with LVEF ≥50% (preserved) will be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Composite outcome of all-cause mortality and worsening heart failure
We will measure a composite outcome of all-cause mortality and worsening heart failure in a 6-month period. Worsening heart failure will be defined as rehospitalization for any cause, urgent emergency room visits for heart failure, or visits to the Heart Failure Unit with administration of iv diuretics.
Time frame: From enrollment to the end of the 6-month period after hospital discharge.
All cause mortality
All-cause mortality will be determined in a 6-month period by using information from the electronic health records.
Time frame: From enrollment to the end of the 6-month period after hospital discharge.
Hospitalization for any cause
Hospitalizations for any cause in a 6-month period will be recorded by review of the electronic health records.
Time frame: From enrollment to the end of the 6-month period after hospital discharge.
Emergency room (ER) visits for heart failure
ER visits for heart failure will be recorded in a 6-month period by reviewing health care electronic records.
Time frame: From enrollment to the end of the 6-month period after hospital discharge.
Need for intravenous diuretics in a Heart Failure Unit visit
All episodes of Heart Failure Unit visits requiring intravenous diuretic administration will be recorded by reviewing electronic health records in a 6-month period.
Time frame: From enrollment to the end of the 6-month period after hospital discharge.
Plan to share: Undecided
Started May 2026 (actual). Primary completion is estimated for Oct 2027, 17 months after the start.
Of 192 non-industry observational studies under Sarcopenia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 63. This study's planned 17 months is below that.
Counting every sponsor, half of 194 studies reached it within 26 months; a quarter within 12 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal